A Study of the Safety, Tolerability, and Pharmacokinetics of MEDI0618 in Healthy Volunteers

This is a randomised, placebo-controlled study of the safety and tolerability of single doses of MEDI0618 in healthy volunteer participants.

This is a randomised, double-blind, placebo-controlled study of the safety, tolerability, and pharmacokinetics of single ascending doses of MEDI0618 in healthy male and female volunteers. This study will include 9 planned cohorts; 8 cohorts will receive single ascending doses of MEDI0618 or placebo by intravenous (IV) administration, 1 cohort will receive MEDI0618 or placebo by subcutaneous (SC) administration. All participants will undergo scheduled safety, tolerability, pharmacokinetics, and immunogenicity assessments while in the clinical unit and as outpatients to the end of the follow-up period.